Clinical、metabolomics and the Study of Intestinal Flora of Jinfeng Pills in the Treatment of Polycystic Ovary Syndrome

Inclusion Criteria: 1. Meet the diagnostic criteria for PCOS: refer to the 2003 Rotterdam standard. 2. In the past 1 month, no relevant drugs or surgery were used, including periodic use of progesterone, short-acting compound oral contraceptives, sequential treatment of estrogen progesterone, spironolactone, pioglitazone, acarboxylose, and related Chinese medicine. 3. Subjects (or their legal representatives) must understand the nature of the study and sign informed consent. 4. Patients with other chronic diseases under stable control should maintain the original treatment regimen during the study period. Exclusion Criteria: 1. Patients with other endocrine diseases, such as adrenal cortical hyperplasia or tumor, Cushing's syndrome, thyroid disease, hyperprolactinemia, androgen secreting tumors, etc.; 2. Patients who have used related drugs in the past 1 month, including sex hormone drugs, insulin sensitizers, including metformin, liraglutide and other drugs; 3. Substance abuse or dependence (alcohol or drugs) within the past 3 months; Heavy smokers (smokers who smoke 20 or more cigarettes a day); 4. Patients with serious or unstable physical diseases, including liver, kidney, gastrointestinal, cardiovascular, respiratory, endocrine, neurological, immune or blood system diseases, mental disorders; 5. Lactating or pregnant women, or women within 1 year after childbirth; 6. Previous allergy to the experimental drug; 7. History of thromboembolic disease or tendency to thrombosis; 8. Participated in a clinical trial of another investigational drug within 1 month prior to inclusion in this study (first interview); 9. Those who meet the inclusion criteria, do not follow medical advice, cannot judge the efficacy or have incomplete data to evaluate the efficacy.